RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/32704112http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/32704112http://www.w3.org/2000/01/rdf-schema#comment"The clinical features of EBV-positive diffuse large B cell lymphoma (DLBCL) indicate a poorer prognosis than EBV-negative DLBCL. Currently, there is no efficacious drug for EBV-positive DLBCL. The cytokine interleukin-21 (IL-21) has been reported to be pro-apoptotic in DLBCL cell lines and is being explored as a new therapeutic strategy for this type of lymphomas. However, our previous studies showed that IL-21 stimulation of EBV-positive DLBCL cell lines leads to increased proliferation. Here, analysis of a rare clinical sample of EBV-positive DLBCL, in combination with a NOD/SCID mouse xenograft model, confirmed the effect of IL-21 on the proliferation of EBV-positive DLBCL cells. Using RNA-sequencing, we identified the pattern of differentially-expressed genes following IL-21 treatment and verified the expression of key genes at the protein level using western blotting. We found that IL-21 upregulates expression of the host MYC and AP-1 (composed of related Jun and Fos family proteins) and STAT3 phosphorylation, as well as expression of the viral LMP-1 protein. These proteins are known to promote the G1/S phase transition to accelerate cell cycle progression. Furthermore, in NOD/SCID mouse xenograft model experiments, we found that IL-21 treatment increases glucose uptake and angiogenesis in EBV-positive DLBCL tumours. Although more samples are needed to validate these observations, our study reconfirms the adverse effects of IL-21 on EBV-positive DLBCL, which has implications for the drug development of DLBCL."xsd:string
http://purl.uniprot.org/citations/32704112http://purl.org/dc/terms/identifier"doi:10.1038/s41598-020-69227-0"xsd:string
http://purl.uniprot.org/citations/32704112http://purl.uniprot.org/core/author"Chen J."xsd:string
http://purl.uniprot.org/citations/32704112http://purl.uniprot.org/core/author"Dong H."xsd:string
http://purl.uniprot.org/citations/32704112http://purl.uniprot.org/core/author"Cai X."xsd:string
http://purl.uniprot.org/citations/32704112http://purl.uniprot.org/core/author"Cui X."xsd:string
http://purl.uniprot.org/citations/32704112http://purl.uniprot.org/core/author"Cai L."xsd:string
http://purl.uniprot.org/citations/32704112http://purl.uniprot.org/core/author"Fan L."xsd:string
http://purl.uniprot.org/citations/32704112http://purl.uniprot.org/core/author"Li J."xsd:string
http://purl.uniprot.org/citations/32704112http://purl.uniprot.org/core/author"Hao Y."xsd:string
http://purl.uniprot.org/citations/32704112http://purl.uniprot.org/core/author"Wang C."xsd:string
http://purl.uniprot.org/citations/32704112http://purl.uniprot.org/core/author"Wang Y."xsd:string
http://purl.uniprot.org/citations/32704112http://purl.uniprot.org/core/author"Xu W."xsd:string
http://purl.uniprot.org/citations/32704112http://purl.uniprot.org/core/author"Zhang Y."xsd:string
http://purl.uniprot.org/citations/32704112http://purl.uniprot.org/core/author"Tong Y."xsd:string
http://purl.uniprot.org/citations/32704112http://purl.uniprot.org/core/author"Wu S."xsd:string
http://purl.uniprot.org/citations/32704112http://purl.uniprot.org/core/author"Wu L."xsd:string
http://purl.uniprot.org/citations/32704112http://purl.uniprot.org/core/author"Ge F."xsd:string
http://purl.uniprot.org/citations/32704112http://purl.uniprot.org/core/author"Xie W."xsd:string
http://purl.uniprot.org/citations/32704112http://purl.uniprot.org/core/author"Feng C."xsd:string
http://purl.uniprot.org/citations/32704112http://purl.uniprot.org/core/author"Gu H.F."xsd:string
http://purl.uniprot.org/citations/32704112http://purl.uniprot.org/core/author"Mou C."xsd:string
http://purl.uniprot.org/citations/32704112http://purl.uniprot.org/core/date"2020"xsd:gYear
http://purl.uniprot.org/citations/32704112http://purl.uniprot.org/core/name"Sci Rep"xsd:string